Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Musculoskeletal

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 3 · 60%High 1 · 20%

Withdrawals due to adverse events · Patients with osteoarthritis of the knee or hip

Paracetamol showed no clear difference in withdrawals due to adverse events 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Paracetamol versus placebo for knee and hip osteoarthritis 2019 · Cochrane Headline outcomes only
RR 1.19 [0.91, 1.55]
7 studies · 3023 participants
Moderate

Total adverse events: number experiencing 24 weeks · Patients with osteoarthritis of the knee or hip

Paracetamol showed no clear difference in total adverse events: number experiencing 24 weeks compared with placebo (high certainty).

1 finding from 1 review

Paracetamol versus placebo for knee and hip osteoarthritis 2019 · Cochrane Headline outcomes only
RR 1.01 [0.92, 1.11]
8 studies · 3252 participants
High

Serious adverse events: number experiencing 24 weeks · Patients with osteoarthritis of the knee or hip

Paracetamol showed no clear difference in serious adverse events: number experiencing 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Paracetamol versus placebo for knee and hip osteoarthritis 2019 · Cochrane Headline outcomes only
RR 1.36 [0.73, 2.53]
6 studies · 3209 participants
Moderate

All adverse events · patients with inflammatory arthritis on methotrexate

1 finding from 1 review

Withdrawal due to adverse events Methotrexate discontinuation · patients with inflammatory arthritis on methotrexate

1 finding from 1 review